Drug Abuse

Addolorato G., et al. (1999) ‘GHB in the treatment of alcohol withdrawal
syndrome: a randomised comparative study versus a benzodiazepine’,
Alcoholism: Clinical and Experimental Research, 23 (No 10), pp.
1596–1604.

Anderson, D. T. and Kuwahara, T. (1997) ‘Endogenous GHB levels in post
mortem specimens’, Proc. California Association of Toxicologists, United
States.

Anderson, R. A., Ritzmann, R. F. and Tabakoff, B. (1977) ‘Formation of GHB
in brain’, Journal of Neurochemistry, 28, pp. 633–9.

Appleton, P. J. and Burn, J. M. B. (1968) ‘A neuroinhibitory substance: GHB,
preliminary report of first clinical trial in Britain’, Anesthesia Analgesia
Current Research, 47, pp. 164–70.

Australian Drug Foundation (ADF),

Badcock, N. R. and Zotti, R. (1999) ‘Rapid screening test for GHB in urine’,
Therapeutic Drug Monitoring, 21, p. 376.

Baselt, R. C. (2000) ‘GHB’ in Disposition of Toxic Drugs and Chemicals in
Man, 5th Edition, Chemical Toxicology Institute, California, pp. 386–8.

Benavides, J., Rumigny, J. F. et al. (1982) ‘High affinity binding site for GHB
in rat brain’, Life Sciences, 30, pp. 953–61.

Benavides, J. et al. (1982) ‘A high affinity, Na+ dependent uptake system for
GHB in membrane vesicles prepared from rat brain’, Journal of
Neurochemistry, 38, pp. 1570–5.

Bessman, S. P. and Fishbein, W. N. (1963) ‘Gamma-hydroxybutyrate, a normal
brain metabolite’, Nature, 200 (No 4912), pp. 1207–8.

Bowey, N. G. (1989) ‘GABAB receptors and their significance in mammalian
pharmacology’, Trends in Pharmacological Sciences, 10, pp. 401–7.

Broughton, R., and Mamelak, M. (1979) ‘The treatment of narcolepsy-cataplexy
with nocturnal GHB’, Canadian Journal of Neurological Sciences, 6,
pp. 1–6.

Bustos, G. and Roth, R. H. (1972) ‘Effect of GHB on the release of
monoamines from the rat striatum’, British Journal of Pharmacology, 44,
pp. 817–820.

Cabrera, R., Torrecilla, J. M., et al. (1998) ’Gammahidroxibutirato (GHB)’,
Manual de Drogodependencias, pp. 151–3.

CAM, (1999) ‘Evaluation des risques relatifs au Gammahydroxybutyrate
(GHB)’, Coordinatiepunt Assessment en Monitoring Nieuwe Drugs (CAM),
The Hague, Netherlands.

Cash, C. D. (1994) ‘GHB: an overview of the pros and cons for it being a
neurotransmitter and/or a useful therapeutic agent’, Neuroscience and
Biobehavioral Reviews, 18 (No 2), pp. 291–304.

Center for Disease Control (CDC) (1999) ‘Adverse events associated with
ingestion of GBL — Minnesota, New Mexico and Texas 1998–1999’,
Morbidity and Mortality Weekly Report, 48 (No 7), pp. 137–40.

Center for Disease Control (CDC) (1997) ‘GHB use’, Morbidity and Mortality
Weekly Report, 46, pp. 281–3.

Center for Disease Control (CDC) (1990) ‘Epidemiologic notes and reports
multistate outbreak of poisoning associated with illicit use of GHB’,
Morbidity and Mortality Weekly Report, 39, (No 47), pp. 861–3.

Center for Disease Control (CDC) (1997) ‘GHB use — New York and Texas
1995–1996’, Morbidity and Mortality Weekly Report, Vol. 46 (No 13):
281–3.

Cheramy, A., Nieoullon, A. and Glowinski, J. (1977) ‘Stimulating effects of
GHB on dopamine release from the caudate nucleus and the substantia nigra
of the cat’, Journal of Pharmacology and Experimental Therapeutics, 203,
pp. 283–93.

Chin, M-Y., Kreutzer, R. A. and Dyer, J. E. (1992) ‘Acute poisoning from GHB
in California’, Western Journal of Medicine, 156, pp. 380–4.

Chin, R. L. et al. (1998) ‘Clinical course of GHB overdose’, Annals of
Emergency Medicine, 31 (No 6), pp. 716–22.

Colombo, G. et al. (1995) ‘Oral self-administration of GHB in the rat’,
European Journal of Pharmacology, 285 pp. 103–7.

Couper, F. J. and Logan, B. K. (2000) ‘Determination of GHB in biological
specimens by GC-MS’, Journal of Analytical Toxicology, 24, pp. 1–7.

Davis, L. G. (1999) ‘Fatalities attributed to GHB and related compounds’,
Southern Medical Journal, 92 (No 10), p. 1037.

De Feudis, F. and Collier, B. (1976) ‘Amino acids of brain and GHB-induced
depression’, Archives of International Pharmacodynamics and Therapeutics,
187, pp. 30–6.

Delay, J. et al. (1993) ‘GHB and narcolepsy: a double blind placebo-controlled
study’, Sleep, 16, pp. 216–20.

Diedrich, U. et al. (1996) ‘GHB in the treatment of increased intracranial
pressure and vasospasm’, Aktuelle Neurologie, 23 (No 2), pp. 63–67.

Dyer, J. E., Kreutzner, R. et al. (1991) ‘Multistate outbreak of poisoning associated
with illicit use of GHB’, Journal of American Medical Association,
265, pp. 447–8.

Dyer, J. E. (1991) ‘GHB: a health food product producing coma and seizurelike
activity’, American Journal of Emergency Medicine, 9 (No 4), pp. 321–4.

Dyer, J. E., Isaacs, S. M. and Keller, K. H. (1994) ‘GHB-induced coma with
serum and urine drug levels’, Veterinary and Human Toxicology, 36, p. 348.

Dyer, J. E., Galbo, M. J. and Andrews, K. M. (1997) ‘1,4-butanediol, ‘pine
needle oil’; overdose mimics toxic profile of GHB’, Journal of Clinical
Toxicology, 35, p. 554.

Eckstein, M. et al. (1999) ‘GHB: report of mass intoxication and review of
literature’, Prehospital Emergency Care, 3 (No 4), pp. 357–61.

El Sohley, M. A. and Salamone, S. J. (1999) ‘Prevalance of drugs used in
cases of alleged sexual assault’, J. Anal. Toxicology, 23 (No 3), pp. 141–6.

Elliott, S. P. (2000) ‘Analysis of GHB in biological fluid using gas chromatography’,
Meeting of Association Clinical Biochemists (ACB),
Birmingham, United Kingdom, 2000.

Elliott, S. P. (2000) Review of the Pharmacotoxicological Data on Gamma-
Hydroxybutyric Acid (GHB), City Hospital NHS Trust, Birmingham, United
Kingdom, Report commissioned by the EMCDDA for the risk assessment on
GHB in the framework of the joint action on new synthetic drugs.

EMEA (2000) Contribution to the Risk Assessment (EMEA/H/9199/01),
London, United Kingdom.

Entholzner, E. et al. (1995) ‘EEG changes during sedation with GHB’,
Anaesthetist, 44 (No 5), pp. 345–50.

EROWID,

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA),
Lisbon, Portugal. Personal Communication.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
(2000) Scientific Monograph 4, Understanding and Responding to Drug Use:
The role of qualitative research, Lisbon, Portugal.

Europol (2000) Contribution to the risk assessment (2564-107), The Hague,
Netherlands.

Fadda, F. et al. (1989) ‘Suppression by GHB of ethanol withdrawal in rats’,
Alcohol and Alcoholism, 24, pp. 447–51.

Feigenbaum, J. J. and Howard, S. G. (1996) ‘Does GHB inhibit or stimulate
central DA release?’, International Journal of Neurosciences, 88 (No 1-2),
pp. 53–69.

Ferrara, S. D. et al. (1993) ‘Therapeutic GHB monitoring on plasma and
urine by GC-MS’, Journal of Pharmaceutical and Biomedical Analysis, 11
(No 6), pp. 483–7.

Ferrara, S. D., Tedeschi, L., Frison, G. and Rossi, A. (1995) ‘Fatality due to
GHB and heroin intoxication’, Journal of Forensic Sciences, 40 (No 3),
pp. 501–4.

Ferrara, S. D. et al. (1999) ‘Effects of single dose of GHB and lorazepam on
psychomotor performance and subjective feelings in healthy volunteers’,
European Journal of Clinical Pharmacology, 54 (No 11), pp. 821–7.

Fieler, E. L., Coleman, D. E. and Baselt, R. C. (1998) ‘GHB concentrations in
pre and post mortem blood and urine’, Clinical Chemistry, 44, p. 692.

Food and Drug Administration (FDA) (1990) ‘GHB warning’, FDA News, 8
(No 11), pp. 1–2.

Food and Drug Administration (FDA) (1997) ‘Updates: injuries, deaths linked
again to GHB abuse’, FDA Consumer, 31, p. 2.

Gallimberti, L. et al. (1989) ‘GHB for treatment of alcohol withdrawal syndrome’,
Lancet II, pp. 787–9.

Gallimberti, L. et al. (1992) ‘GHB in the treatment of alcohol dependence: a
double blind study’, Alcoholism: Clinical and Experimental Research, 16
(No 4), pp. 673–76.

Gallimberti, L. et al. (1993) ‘GHB for treatment of opiate withdrawal syndrome’,
Neuropsychopharmacology, 9 (No 1), pp. 77–81.

Galloway G. P. et al. (1997) ‘Gamma-hydroxybutyrate (GHB): an emerging
drug of abuse that causes physical dependence’, Addiction, 92 (No 1),
pp. 89–96.

Giarman, N. J. and Schmidt, K. F. (1963) ‘Some neurochemical aspects of the
depressant action of gamma-butyrolactone (GBL) on the central nervous system’,
British Journal of Pharmacology, 20, pp. 563–8.

Gessa, G. L. et al. (1966) ‘Selective increase of brain dopamine induced by
GHB’, Life Sciences, 5, pp. 1921–30.

Godbout, R. et al. (1991) ‘Inhibitory influence of the mesocortical dopaminergic
neurons on their target cells: electrophysiological and pharmacological
characteristics’, Journal of Pharmacology and Experimental Therapeutics,
258, pp. 728–38.

Godbout, R. et al. (1995) ‘Effect of GHB and its antagonist NCS-382 on
spontaneous cell firing in the firing in the prefrontal cortex of the rat’, Brain
Research, 673, pp. 157–60.

Hale, K. A., Regional Laboratory for Toxicology, Birmingham, United
Kingdom. Personal Communication.

Hechler, V., Gobaille, S. et al. (1991) ‘Extracellular events induced by GHB
in striatum in micro-dialysis study’, Journal of Neurochemistry, 56,
pp. 938–44.

Helrich, M., McAslan, T. C., Skolnick, S. and Bessman, S. P. (1964)
‘Correlation of blood levels of GHB with state of consciousness’,
Anesthesiology, 25, pp. 771–5.

Hernandez, M. et al. (1998) ‘GHB-induced Delirium: A Case report and
Review of the Literature on Gamma Hydroxybutyric Acid’, American Journal
of Drug and Alcohol Abuse, 24 (10), pp. 179–83.

Hoes, M., Vree, T. B. and Guelen P. J. M. (1980) ‘GHB as a hypnotic’,
L’Encephale, 6, pp. 93–9.

Hovda, K. E., Liberg, J. P., Nordby, G. and Jacobsen, D. (1998) ‘GHB — an
endogenous substance and an intoxicant’, Tidskkr. Nor. Laegeforen., 118
(No 28), pp. 4390–3.

Hunderup, M. C. and Jorgensen, A. J. (1999) ‘Poisoning with gamma-hydroxybutyric
acid’, Cases reported in connection with ‘cultural festivals’ in
August 1999 in Kolding, Ugesker Laeger, 161 (No 50), pp. 6939–40.

Kam, P. C. A. and Yoong, F. F. Y. (1998) ‘Gamma-hydroxybutyric acid: an
emerging recreational drug’, Anaesthesia, 53, pp. 1195–8.

Kato, Y., Nakai, Y., Imura, H., Chinara, K. and Ohgo, S. (1974) ‘Effect of 5-
hydroxytryptophan (5-HTP) on plasma prolactin levels in man’, Journal of
Clinical Endocrinology & Metabolism, 38, p. 695.

Kaufman, E. E., Nelson, T., Goochee, C. and Sokoloff, L. (1979) ‘The purification
and characterisation of a NADP+-linked alcohol oxido-reductase
which catalyses the interconversion of GHB and succinic semialdehyde’,
Journal of Neurochemistry, 32, pp. 699–712.

Kleinschmidt, S. et al. (1995) ‘GHB — Hat sie einen Stellenwert in
Anästhesie und Intensivmedizin?’, Anästhesiol. Intensivemed.
Schmerztherapie, 30, pp. 393–402.

Knudsen, K. (2000) ‘Intoxication with GHB is an increasing social and medical
emergency in Sweden’, 20th International Congress of the European
Association of Poison Centres and Clinical Toxicologists (EAPCCT),
Amsterdam, Netherlands.

Laborit, H. (1964) ‘Sodium 4-hydroxybutyrate’, International Journal of
Neuropharmacology, 3, pp. 433–49.

Laborit, H. (1972) ‘Correlations between protein and serotonin synthesis during
various activities of the central nervous system (slow and desynchronised)
sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness
and pharmacological action of sodium gamma-hydroxybutyrate’,
Research Communications in Chemical Pathology and Pharmacology, 3,
pp. 51–81.

Le Gatt, D. F., Singer, P. P. and Jones, G. R. (1999) ‘GHB on the Internet’,
Clinical Chemistry Supplement A130, 464a.

Lenzenhuber, E. et al. (1999) ‘GHB for therapy of alcohol withdrawal syndrome
in intensive care patients: a comparison between two symptom-triggered
therapeutic regimens’, Anaesthesist, 48 (No 2), pp. 89–96.

Lettieri, J. and Fung, H. L. (1978) ‘Improved pharmacological activity via
pro-drug modification: comparative pharmacokinetics of sodium gammahydroxybutyrate
and GBL’, Research Communications in Chemical
Pathology and Pharmacology, 22, pp. 107–118.

Levy, M. I. et al. (1983) ‘Gamma-hydroxybutyrate in the treatment of schizophrenia’,
Psychiatry Research, 9 (No 1), pp. 1–8.

Li, J., Stokes, S. A. and Woekener, A. (1998) ‘A tale of novel intoxication: seven
cases of GHB overdose’, Annals of Emergency Medicine, 31 (No 6), pp. 723–8.

Li, J., Stokes, S. A. and Woekener, A. (1998) ‘A tale of novel intoxication: a
review of the effects of GHB with recommendations for management’,
Annals of Emergency Medicine, 31 (No 6), pp. 729–36, 1998.

London Toxicology Group,

Louagie, H. K. et al. (1997) ‘A sudden awakening from a near coma after
combined intake of GHB and ethanol’, Journal of Clinical Toxicology, 35
(No 6), pp. 591–4.

The Lycaeum,

McCusker, R. R. et al. (1999) ‘Analysis of GHB in urine by gas chromatography-
mass spectrometry (GC-MS)’, J. Anal. Toxicology, 23, pp. 301–5.

Maitre, M. et al. (1990) ‘A specific GHB receptor ligand possess both antagonistic
and anticonvulsant properties’, Journal of Pharmacology and
Experimental Therapeutics, 255, pp. 657–63.

Mamelak, M., Escruin, J. M. and Stokan, O. (1977) ‘The effects of GHB on
sleep’, Biological Psychiatry, 12 (No 2), pp. 273–88.

Mamelak, M., Scharf, M. B. and Woods, M. (1986) ‘Treatment of narcolepsy
with GHB — a review of clinical and sleep laboratory findings’, Sleep, 9
(No 1), pp. 285–9.

Mamelak, M. (1989) ‘Gamma-hydroxybutyrate: an endogenous regulator of
energy metabolism’, Neuroscience and Biobehavioral Reviews, 13,
pp. 187–98.

Mandel, P., Maitre, M., Vayer, P. et al. (1987) ‘Function of GHB: a putative
neurotransmitter’, Biochemistry Society Transactions, 15, pp. 215–7.

Marcus, R., Winter, W., Mori, K. and Spooner, C. (1967) ‘EEG and behavioural
comparison of the effects of GHB, GBL and short chain fatty acids in
the rat’, International Journal of Neuropharmacology, 6, pp. 175–85.

Mathivet, P. et al. (1997) ‘Binding characteristics of GHB as a weak but
selective GABAB receptor agonist’, European Journal of Pharmacology, 321,
pp. 67–75.

Maxwell, R. and Roth, R. H. (1971)‚ ‘Conversion of 1,4-butanediol to GHB
in rat brain and in peripheral tissue’, Biochemical Pharmacology, 21,
p. 1521.

Médecins du Monde, (1999) Rapport de Recherche-Action: Usages de
Drogues de Synthese (Ecstasy, LSD, Dance-pills, Amphetamines …) Paris,
France.

Metcalf, D. R., Emde, R. N. and Stripe, J. T. (1966) ‘An EEG-behavioural
study of sodium hydroxybutyrate in humans’, Electroencephalography and
Clinical Neurophysiology, 20, pp. 506–12.

Microgram (1999) Gamma Hydroxybutyric Acid (GHB) analysed by
Louisiana State Police Crime Laboratory, DEA, Washington.

Mixmag (2000) ‘Drug taking is reaching epidemic proportions’, Issue 110,
Vol. 2, p. 23.

Nelson, T. and Kaufman, E. E. (1994) ‘Developmental time course in the
brain and kidney of two enzymes that oxidise GHB’, Developmental
Neuroscience, 16, pp. 352–8.

Newcombe, R. (1999) ‘Cocaine and GHB: Overview of two new trends in
dance drugs’, Paper presented to the Release Conference June 1999, 3D
Research, Liverpool.

Nissbrandt, H. and Engberg, G. (1996) ‘The GABAB-receptor antagonist,
CGP 35348, antagonises GHB and baclofen-induced alterations in locomotor
activity and forebrain dopamine levels in mice’, Journal of Neural
Transmission, 103, pp. 1255–63.

Palatini, P., Tedeschi, L. et al. (1993) ‘Dose-dependent absorption and elimination
of GHB in healthy volunteers’, European Journal of Clinical
Pharmacology, 45, pp. 353–6.

Personne, M. and Landgren, A. (2000) ‘GHB intoxication in Sweden’, 20th
International Congress of the European Association of Poison Centres and
Clinical Toxicologists (EAPCCT), Amsterdam, Netherlands.

Pichlmeier, R. and Schneck, H. J. (1991) ‘GHB for basic sedation in intensive
care medicine, Intensiv-und Notfallbehandlung’, 16 (No 3), pp. 106–12.

Poldrugo, F. and Snead, O. C. (1984) ‘1,4-butanediol, GHB and ethanol:
relationships and interactions’, Neuropharmacology, 23 (No 1), pp. 109–13.

Pospiech, R. and Schmidt, E. (1993) ‘Use of GHB in patients on long-term respiratory
therapy’, Intensiv-und Notfallbehandlung, 18 (No 4), pp. 157–64.

Rambourg-Schepens, M. O., Buffet, M., Durak, C. and Mathieu-Nolf, M.
(1997) ‘GBL poisoning and its similarities to GHB: two case reports’,
Veterinary and Human Toxicology, 39, pp. 234–5.

Ratomponirina, C., Hode, Y., Hechler, V. and Maitre, M. (1995) ‘GHB receptor
binding in rat brain is inhibited by guanyl nucleotides and pertussis
toxin’, Neuroscience Letters, 189, pp. 51–3.

Roth, R. H. and Giarman, N. J. (1966) ‘GBL and GHB — distribution and
metabolism’, Biochemical Pharmacology, 15, pp. 1333–48.

Roth, R. H. and Giarman, N. J. (1968), ‘Evidence that central nervous system
depression by 1,4-butanediol is mediated through a metabolite, GHB’,
Biochemical Pharmacology, 17, p. 735.

Roth, R. H. and Giarman, N. J. (1969) ‘Conversion in vivo of GABA to GHB
in mammalian brain’, Biochemical Pharmacology, 18, pp. 247–50.

Scarf, M. et al. (1985) ‘The effects and effectiveness of GHB in patients with
narcolepsy’, Journal of Clinical Psychiatry, 46, pp. 222–5.

Schultz, S. C. et al. (1981) ‘Gamma-hydroxybutyrate treatment of schizophrenia:
a pilot study’, Pharmacopsychiatria, 14 (No 4), pp. 129–34.

Scotti de Carolis, A. and Massotti, M. (1978) ‘EEG and behavioural investigations
on ‘gabaergic’ drugs; muscimol, baclofen and sodium hydroxybutyrate
— implications on human epileptic studies’, Progress in Neuro-psychopharmacology
& Biological Psychiatry, 2, pp. 431–2.

Scrima, L. et al. (1990) ‘The effects of GHB on the sleep of narcolepsy
patients: a double blind study’, Sleep, 13, pp. 479–90.

Smith, K.M. (1999) ‘Drugs used in acquaintance rape’, Journal of the
American Pharmaceutical Association (Wash.), 39 (No 4), pp. 519–25.

Smythe, G. A., Brandstater, J. F. and Lazarus, L. (1975) ‘Serotonergic control
of rat growth hormone secretion’, Neuroendocrinology, 17, p. 245.

South, J., ‘Discover the regenerative effects of GHB’, International Antiaging

Systems.

Spano, P. F., Tagliamonte, A., Tagliamonte, P. and Gessa, G. L. (1971)
‘Stimulation of brain dopamine synthesis by GHB’, Journal of
Neurochemistry, 18, pp. 1831–6.

Steel, G. C. (1968) ‘Clinical application of GHB as a sleep cover in lumbar
epidural block’, Proceedings of the Royal Society of Medicine, 61, p. 825.
Steele, M. T. and Watson, W. A. (1995) ‘Acute poisoning from GHB’,
Molecular Medicine, 92 (No 7), pp. 354–7.

Stephens, B. G. and Baselt, R. C. (1994) ‘Driving under the influence of
GHB?’, J. Anal. Toxicology, 18, pp. 357–358.

Stephens, R. G., Coleman, D. E. and Baselt, R. C. (1999) ‘In vivo stability of
endogenous GHB in post mortem blood’, Journal of Forensic Science, 44
(No 1), p. 231.

Stichting Adviesburo Drugs (1990) ‘Een Nieuwe Drugtrend: een beschrijving
over de opkomst en populariteit ven GHB en een analyse over het ontstaan
van de beeldvorming over rape drug’, Amsterdam, Netherlands.

Sturman, P., (2000) ‘Drug assisted sexual assault: a study for the Home Office
under the Police Research Award Scheme’, Home Office, London, United
Kingdom.

Takahara, J. et al. (1977) ‘Stimulatory effects of GHB on growth hormone and
prolactin release in humans’, Journal of Clinical Endocrinology &
Metabolism, 44, pp. 1014–7.

Vandevenne, L., Becker, J., Van de Velde, E. and Verstraete, A. (2000) ‘A case
of GBL overdose’, 20th International Congress of the European Association
of Poison Centres and Clinical Toxicologists (EAPCCT), Amsterdam,
Netherlands, 2000.

Vickers, M. D., (1968) ‘Gamma-hydroxybutyric acid’, Proceedings of the
Royal Society of Medicine, 61, pp. 821–4.

Vickers, M. (1969) ‘Gamma-hydroxybutyric acid’, International
Anesthesiology Clinics, 7, pp. 75–89.

Viera, A. J. and Yates, S. W. (1999) ‘Toxic ingestion of GHB’, Southern
Medical Journal, 92 (No 4), pp. 404–5.

Vree, T. B., Van der Kleijn, E. and Knop, H. J. (1976) ‘Rapid determination of
4-hydroxybutyric acid and 2-propylpentanoate in human plasma by means
of gas-liquid chromatography’, Journal of Chromatography, 121, pp. 150–2.

Walters, J. R., Roth, R. H. and Aghajanian, G. K. (1973) ‘Dopaminergic neurons:
similar biochemical and histochemical effects of GHB and acute
lesions of the nigro-neostriatal pathway’, Journal of Pharmacology and
Experimental Therapeutics, 186, pp. 630–9.

Ward, D., Morgenthaler, J. and Fowkes, S. (1998) GHB — the natural mood
enhancer, Smart Publications, California, United States.

Ward, D. (2000) GHB — the natural mood enhancer: the authoritative guide
to its responsible use, Smart Publications, California, United States.

Williams, H., Taylor, R. and Roberts, M. (1998) ‘Gamma-hydroxybutyrate
(GHB): a new drug of misuse’, Irish Medical Journal, 91 (No 2), pp. 56–7.

Williams, S. R., Turner, J. P. and Crunelli., V. (1995) ‘GHB promotes oscillatory
activity of rat and cat thalamocortical neurons by a tonic GABAB receptor-
mediated hyperpolarization’, Neuroscience, 66, pp. 133–41.

Williams, S. R. (1998) ‘Gamma-hydroxybutyric acid poisoning’, Western
Journal of Medicine, 168 (No 3), pp. 187–8.

Winter, J. C. (1981) ‘The stimulus properties of gamma-hydroxybutyrate’,
Psychopharmacology, 73 (No 4), pp. 372–5.

Winters, W. and Spooner, C. (1965) ‘A neurophysiological comparison of
GHB with pentobarbital in cats’, Clinical Neurophysiology, 18, pp. 287–96.

Woolverton, W. L. et al. (1999) ‘Evaluation of the reinforcing and discriminative
stimulus effects of GHB in rhesus monkeys’, Drug and Alcohol
Dependence, 54 (No 2), pp. 137–43.

Xie, X. and Smart, T. G. (1992) ‘GHB hyperpolarizes hippocampal neurones
by activating GABAB receptors’, European Journal of Pharmacology, 212,
pp. 291–4.

Yamada, Y. et al. (1967) ‘Effect of GBL and GHB on the EEG and sleep cycle
in man’, Electroencephalography and Clinical Neurophysiology, 22,
pp. 558–62.

< Prev		Next >